See all studies
6/29
Safety
N/A
Mfeukeu-Kuate et al. (Preprint) (not included in the study count)
Electrocardiographic safety of daily Hydroxych loroquine 400mg plus Azithromycin 250mg as an ambulatory treatment for COVID-19 patients in Cameroon
No life-threatening modifications of the QT interval was observed in non-severe COVID-19 patients treated ambulatory with HC Q+AZ. 51 relatively young patients 39 +/- 11.
Source   Share   Tweet
See all studies
Please send us corrections, updates, or comments.
Submit